SCM
KDNY

Silverarc Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Silverarc Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,158
Closed -$12.8M – 112
2021
Q2 		$12.8M Buy
+14,158
New +$226K 5.7% 2

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Silverarc Capital Management's KDNY Position: Q3 2021 in Review

Silverarc Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2021, closing a stake of 14,158 shares — an estimated $12.8M sold.

Silverarc Capital Management first reported a position in KDNY in Q2 2021 and held it in 1 quarter. The position peaked at $12.8M in Q2 2021. 85 funds tracked by Wall St. Rank hold KDNY as of Q3 2021.

  • Silverarc Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 14,158 Chinook Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $12.8M.
  • Silverarc Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $12.8M in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.